Manufacturing Made Simple Podcast
Sep 9, 2026 · 24 min · 7 segments
Where do raw materials and APIs actually come from? Andrew traces the journey of an ingredient from source to factory, explains single-source risk and supplier vetting, and addresses the concentration…
Andrew CheungHost
[upbeat music] Let me start by describing how personal care and pharmaceutical supply chains are actually structured, because I think most people who work in these industries know their own piece of the chain well but don't have a clear, um, picture of the full supply chain itself.
At the upstream end of the supply chain are raw materials and ingredient suppliers.
In personal care, these are the companies that produce the emollients, humectants, surfactants, preservatives, actives, uh, fragrances, and even the colorants that goes into the formula.
In pharmaceutical manufacturing, the upstream equivalent is the API manufacturer, the company that synthesizes, extracts, or ferments the active pharmaceutical ingredient, plus the excipient suppliers who produce the non-active components of the drug product.
The raw material and ingredient tier is where geographic concentration is most pronounced and where supply chain disruption risk is at its highest.
Many specialty personal care ingredients, um, novel actives, proprietary botanical extracts, and specific synthesized esters have one or two qualified global manufacturers.
If either of those manufacturers has a production problem, there is no other qualified alternative to really turn to without going through a supplier qualification process that takes months.
In pharmaceutical manufacturing, the API concentration, um, problem is even more acute.
Estimates vary, but the dependencies in certain therapeutic categories like antibiotics, blood pressure medications, diabetes drugs are substantially enough that supply chain disruptions in those two countries have directly caused drug shortages in the US and EU Below the raw material tier is a contract manufacturer, the CMO that processes raw materials into the finished products.
This is the manufacturing step that most brand founders interact with most directly.
The CMO receives the raw materials from approved suppliers, manufactures, uh, the product to the brand specifications, and delivers the finished good or semi-finished goods to the brands for distribution.
They source their own raw materials and run their own manufacturing facilities.
But for most small and mid-sized brands, the CMO relationship is the center of the manufacturing supply chain.
Below the CMO tier is packaging, primary packaging that directly has contact with the product itself, and the secondary packaging for outer cartons and retail presentations.
Tooling and molds that they need to create the packaging can take months to qualify.
And in pharmaceutical manufacturing, the primary container closure system is part of the regulatory submission and cannot be changed without a regulatory amendment.
Understanding that full picture, raw materials, APIs, CMOs, packaging, and distribution is the starting point for supply chain risk assessment because the vulnerabilities don't always sit where people expect them to.
[upbeat music] Let me start by describing how personal care and pharmaceutical supply chains are actually structured, because I think most people who work in these industries know their own piece of the chain well but don't have a clear, um, picture of the full supply chain itself.
At the upstream end of the supply chain are raw materials and ingredient suppliers.
In personal care, these are the companies that produce the emollients, humectants, surfactants, preservatives, actives, uh, fragrances, and even the colorants that goes into the formula.
In pharmaceutical manufacturing, the upstream equivalent is the API manufacturer, the company that synthesizes, extracts, or ferments the active pharmaceutical ingredient, plus the excipient suppliers who produce the non-active components of the drug product.
The raw material and ingredient tier is where geographic concentration is most pronounced and where supply chain disruption risk is at its highest.
Many specialty personal care ingredients, um, novel actives, proprietary botanical extracts, and specific synthesized esters have one or two qualified global manufacturers.
If either of those manufacturers has a production problem, there is no other qualified alternative to really turn to without going through a supplier qualification process that takes months.
In pharmaceutical manufacturing, the API concentration, um, problem is even more acute.
Estimates vary, but the dependencies in certain therapeutic categories like antibiotics, blood pressure medications, diabetes drugs are substantially enough that supply chain disruptions in those two countries have directly caused drug shortages in the US and EU Below the raw material tier is a contract manufacturer, the CMO that processes raw materials into the finished products.
This is the manufacturing step that most brand founders interact with most directly.
The CMO receives the raw materials from approved suppliers, manufactures, uh, the product to the brand specifications, and delivers the finished good or semi-finished goods to the brands for distribution.
They source their own raw materials and run their own manufacturing facilities.
But for most small and mid-sized brands, the CMO relationship is the center of the manufacturing supply chain.
Below the CMO tier is packaging, primary packaging that directly has contact with the product itself, and the secondary packaging for outer cartons and retail presentations.
Tooling and molds that they need to create the packaging can take months to qualify.
And in pharmaceutical manufacturing, the primary container closure system is part of the regulatory submission and cannot be changed without a regulatory amendment.
Understanding that full picture, raw materials, APIs, CMOs, packaging, and distribution is the starting point for supply chain risk assessment because the vulnerabilities don't always sit where people expect them to.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
